Latest Articles about SUPN

Tentative Approval for SUPN Candidate - Analyst Blog

Zacks Equity Research — Wed, 12 Jun 2013 00:26:47 Z

Supernus Pharmaceuticals, Inc. ( SUPN ) recently received tentative US Food & Drug Administration (FDA) approval for Trokendi XR. Trokendi XR is a novel once-daily extended release

After Hours Most Active for May 24, 2013 : CXW, QQQ, PFE, WD, SAN, FRAN, FIG, BAC, MSFT, SUPN, NTAP, CSCO

NASDAQ.com News — Sat, 25 May 2013 00:40:58 Z

The NASDAQ 100 After Hours Indicator is down -.7 to 2,990.32. The total After hours volume is currently 11,685,721 shares traded. The following are the most active stocks for the after

Narrower-than-Expected Loss at Supernus - Analyst Blog

Zacks Equity Research — Tue, 14 May 2013 18:21:01 Z

Supernus Pharmaceuticals, Inc. ( SUPN ) reported first quarter 2013 net loss per share of 60 cents, narrower than the Zacks Consensus Estimate of a loss of 63 cents and the year-ago loss

Bearish MACD for Supernus Pharmaceuticals Inc. - Tale of the Tape

Zacks Equity Research — Tue, 23 Apr 2013 20:13:44 Z

Supernus Pharmaceuticals Inc. 's ( SUPN ) MACD indicator has moved into bearish territory with a reading of -0.3009. The Zacks Rank #4 ("Sell") stock decreased more than 0.19%

Supernus Pharmaceuticals Reports Insider Buys

Monica Wolfe — Wed, 27 Mar 2013 03:24:23 Z

With its share prices in a downward slump, two insiders picked up nearly 40,000 shares in Supernus Pharmaceuticals ( SUPN ) this past week. The buying trend started on March 14 when Gregory

Loss Narrows at Supernus - Analyst Blog

Zacks Equity Research — Sat, 16 Mar 2013 00:23:01 Z

Supernus Pharmaceuticals, Inc. ( SUPN ) reported fourth quarter 2012 net loss per share of 51 cents, narrower than the Zacks Consensus Estimate of a loss of 73 cents. In the fourth quarter

Pipeline Advances at Supernus - Analyst Blog

Zacks Equity Research — Tue, 27 Nov 2012 04:11:01 Z

Supernus Pharmaceuticals, Inc. ( SUPN ) recently announced encouraging top-line results from a phase IIb study, which is evaluating its attention deficit and hyperactivity disorder (ADHD)

Street research for Supernus Pharmaceuticals expected on May 27

Renaissance Capital — Tue, 22 May 2012 15:00:15 Z

Street research for Supernus Pharmaceuticals, a former Shire sub developing improved drug formulations for epilepsy and ADHD, is expected to be released on 5/27/12. On 4/30/12, the